Price T Rowe Associates Inc Lexicon Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 117,179 shares of LXRX stock, worth $97,258. This represents 0.0% of its overall portfolio holdings.

Number of Shares

117,179

Previous 117,179 -0.0%

Holding current value

$97,258

Previous $197,000 6.6%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.54 - $2.28 $18,270 - $27,049	11,864 Added 11.27%	117,179 $197,000
Q1 2024 May 15, 2024	BUY	$1.3 - $3.58 $6,011 - $16,553	4,624 Added 4.59%	105,315 $253,000
Q3 2023 Nov 14, 2023	SELL	$1.06 - $2.33 $8,156 - $17,929	-7,695 Reduced 7.1%	100,691 $110,000
Q2 2023 Aug 14, 2023	SELL	$2.15 - $3.49 $103,705 - $168,340	-48,235 Reduced 30.8%	108,386 $249,000
Q1 2023 May 15, 2023	SELL	$1.99 - $2.68 $74,609 - $100,478	-37,492 Reduced 19.31%	156,621 $381,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $2.56 $1,508 - $2,145	838 Added 0.43%	194,113 $371,000
Q3 2022 Nov 14, 2022	SELL	$1.94 - $3.43 $8,082 - $14,289	-4,166 Reduced 2.11%	193,275 $464,000
Q2 2022 Aug 15, 2022	BUY	$1.31 - $2.69 $56,996 - $117,039	43,509 Added 28.27%	197,441 $367,000
Q1 2022 May 16, 2022	BUY	$1.95 - $3.89 $20,085 - $40,067	10,300 Added 7.17%	153,932 $322,000
Q4 2021 Feb 14, 2022	BUY	$3.81 - $6.16 $53,583 - $86,634	14,064 Added 10.85%	143,632 $566,000
Q2 2021 Aug 16, 2021	BUY	$4.12 - $5.87 $109,744 - $156,359	26,637 Added 25.88%	129,568 $595,000
Q1 2021 May 17, 2021	SELL	$3.45 - $9.09 $266,146 - $701,238	-77,144 Reduced 42.84%	102,931 $604,000
Q4 2020 Feb 16, 2021	BUY	$1.05 - $3.67 $189,078 - $660,875	180,075 New	180,075 $616,000

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $157M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Lexicon Pharmaceuticals, Inc. Transaction History